Evaluating Synthetic Activation and Repression of Neuropsychiatric-Related Genes in hiPSC-Derived NPCs, Neurons, and Astrocytes.
- Authors
- Ho, Seok-Man; Hartley, Brigham J; Flaherty, Erin; Rajarajan, Prashanth; Abdelaal, Rawan; Obiorah, Ifeanyi; Barretto, Natalie; Muhammad, Hamza; Phatnani, Hemali P; Akbarian, Schahram; Brennand, Kristen J
- Year
- 2017
- Journal
- Stem cell reports
- PMID
- 28757163
- DOI
- 10.1016/j.stemcr.2017.06.012
- PMCID
- PMC5550013
Modulation of transcription, either synthetic activation or repression, via dCas9-fusion proteins is a relatively new methodology with the potential to facilitate high-throughput up- or downregulation studies of gene function. Genetic studies of neurodevelopmental disorders have identified a growing list of risk variants, including both common single-nucleotide variants and rare copy-number variations, many of which are associated with genes having limited functional annotations. By applying a CRISPR-mediated gene-activation/repression platform to populations of human-induced pluripotent stem cell-derived neural progenitor cells, neurons, and astrocytes, we demonstrate that it is possible to manipulate endogenous expression levels of candidate neuropsychiatric risk genes across these three cell types. Although proof-of-concept studies using catalytically inactive Cas9-fusion proteins to modulate transcription have been reported, here we present a detailed survey of the reproducibility of gRNA positional effects across a variety of neurodevelopmental disorder-relevant risk genes, donors, neural cell types, and dCas9 effectors.
Experimental Platform to Evaluate dCas9-Mediated Manipulation of Gene Expression in hiPSC-Derived NPCs, Neurons, and Astrocytes(A) Experimental schematic for the generation of hiPSC-derived NPCs, neurons, and astrocytes, including the administration of lentiviral dCas9 and gRNA vectors.(B) Experimental time line for lentiviral transduction (and antibiotic selection) of hiPSC-derived NPCs, neurons, and astrocytes with lentiviral dCas9 and gRNA vectors.(C) gRNA locations (green, blue, and yellow) relative to the TSS of KCTD13, TAOK2, NRXN1, SNAP91, and CLCN3.
Activation of Neuropsychiatric Disorder Risk Genes in hiPSC-Derived NPCs and NGN2 Neurons from Three Individuals(AβF) Normalized relative mRNA levels (compared with no gRNA or scrambled gRNA control as indicated [gray]) following transduction of dCas9VP64 (A, B, C, and E) and dCas9VPR (C, D, and F) in NPCs (A, B, C, and E) and 8-day-old NGN2 neurons (D and F) with lentivirus-expressing gRNAs targeted to three different locations (green, blue, and yellow) upstream of the TSS for KCTD13 (A), TAOK2 (B), NRXN1 (C), SNAP91 (D and E), and CLCN3 (F). C1βC3 indicates hiPSC lines from three independent male controls (see Table S1 for more information); each biological replicate is depicted by a circle.Data are presented as means Β± SEM (bar graph) from at least three independent biological replicates. βp < 0.05, ββp < 0.01, βββp < 0.001, ββββp < 0.0001.
Repression of Neuropsychiatric Disorder Risk Genes in hiPSC-Derived NPCs and NGN2 Neurons from Three Individuals(AβF) Normalized relative mRNA levels (compared with no gRNA control [gray]) following transduction of dCas9KRAB NPCs (A, B, and E), 8-day-old (C and F), and 20-day-old (D) NGN2 neurons with lentivirus-expressing gRNAs targeted to different locations (green, blue, and yellow) upstream of the TSS for KCTD13 (A), TAOK2 (B), SNAP91 (C, D, and E), and CLCN3 (F). C1βC3 indicates hiPSC lines from three independent male controls (see Table S1 for more information); each biological replicate is depicted by a circle.Data are presented as means Β± SEM (bar graph) from at least three independent biological replicates. βp < 0.05, ββp < 0.01, βββp < 0.001, ββββp < 0.0001.
Activation of Neuropsychiatric Disorder Risk Genes in NPC-Derived Astrocytes from Three Individuals(A) Representative FACS validation of NPC-astrocytes, using antibodies for GFAP (left), S100Ξ² (middle), and EAAT1 (right).(B) Representative immunofluorescent image of NPC-astrocytes stained with vimentin (green) and DAPI (blue). Scale bar, 20 ΞΌm.(C) FACS validation of Cas9 protein levels in dCas9-VP64 NPC-astrocytes.(D and E) Normalized relative mRNA levels (compared with no gRNA control [gray]) following transduction of dCas9VP64 NPC-astrocytes with lentivirus-expressing gRNAs targeted to three different locations (green, blue, and yellow) upstream of the TSS for KCTD13 (D) and SNAP91 (E). C1βC3 indicates hiPSC lines from three independent male controls (see Table S1 for more information); each biological replicate is depicted by a circle.Data are presented as means Β± SEM (bar graph) from at least three independent biological replicates. βp < 0.05, βββp < 0.001, ββββp < 0.0001.
Single and Multiplexed IVT gRNA-Mediated Transcriptional Modulation(A) Transient expression of IVT gRNAs for transcriptional modulation of SNAP91 (1 gRNA), CEP162 (six pooled gRNAs), and FUT9 (ten pooled gRNAs). Normalized relative mRNA levels (compared with GFP [SNAP91] or ten gRNAs targeting a nearby non-promoter non-coding region [CEP162 and FUT9]) following transfection of dCas9VP64 NPCs with IVT gRNAs targeted upstream of the TSS for SNAP91, CEP162, and FUT9.(B) Multiplexed pools of ten, five (two independent pools), and one IVT gRNA(s) for transcriptional modulation of FUT9.Data are presented as means Β± SEM (bar graph) from at least three independent biological replicates. Each biological replicate is depicted by a circle. βp < 0.05, ββp < 0.01, βββp < 0.001.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | 2018 | 29897633 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Functional implications of polygenic risk for schizophrenia in human neurons. | Michael Deans PJ et al. | β | 2026 | β |
| A Blueprint for Translational Precision Medicine in Autism Spectrum Disorder and Related Neurogenetic Syndromes. | Thom RP et al. | β | 2025 | β |
| An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome. | Thakur P et al. | β | 2025 | β |
| Epigenetic Regulation of G6PD Drives Metabolic Reprogramming in Intrahepatic Cholangiocarcinoma. | Nakano Y et al. | β | 2025 | β |
| Molecular signature of primate astrocytes reveals pathways and regulatory changes contributing to human brain evolution. | Ciuba K et al. | β | 2025 | β |
| Patient-derived models of <i>UBA5-</i>associated encephalopathy identify defects in neurodevelopment and highlight potential therapeutic avenues. | Chen H et al. | β | 2025 | β |
| PICALM Alzheimer's risk allele causes aberrant lipid droplets in microglia. | Kozlova A et al. | β | 2025 | β |
| Promoter hijacking by primate LINC00473 disrupts an ancestral CREB-PDE10A feedback loop | Squires SJ et al. | β | 2025 | β |
| Validation of human sensory neurons derived from inducible pluripotent stem cells as a model for latent infection and reactivation by herpes simplex virus 1. | Oh HS et al. | β | 2025 | β |
| A modular dCas9-based recruitment platform for combinatorial epigenome editing. | Swain T et al. | β | 2024 | β |
| Targeted CRISPR activation is functional in engineered human pluripotent stem cells but undergoes silencing after differentiation into cardiomyocytes and endothelium. | Karbassi E et al. | β | 2024 | β |
| Therapeutic validation of MMR-associated genetic modifiers in a human exΒ vivo model of Huntington disease. | Ferguson R et al. | β | 2024 | β |
| Upregulated GIRK2 Counteracts Ethanol-Induced Changes in Excitability and Respiration in Human Neurons. | Prytkova I et al. | β | 2024 | β |
| CRaTER enrichment for on-target gene editing enables generation of variant libraries in hiPSCs. | Friedman CE et al. | β | 2023 | β |
| CRISPRi gene modulation and all-optical electrophysiology in post-differentiated human iPSC-cardiomyocytes. | Han JL et al. | β | 2023 | β |
| Integrating genetics and transcriptomics to study major depressive disorder: a conceptual framework, bioinformatic approaches, and recent findings. | Hicks EM et al. | β | 2023 | β |
| Relationship between lysine methyltransferase levels and heterochromatin gene repression in living cells and in silico. | Yan X et al. | β | 2023 | β |
| The genome-wide mutational consequences of DNA hypomethylation. | Besselink N et al. | β | 2023 | β |
| The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency. | Sperber HS et al. | β | 2023 | β |
| Combinatorial Approach of Binary Colloidal Crystals and CRISPR Activation to Improve Induced Pluripotent Stem Cell Differentiation into Neurons. | Urrutia-Cabrera D et al. | β | 2022 | β |
| CRISPR-Based Tools for Fighting Rare Diseases. | Li Q et al. | β | 2022 | β |
| CRISPR/Cas-Based Approaches to Study Schizophrenia and Other Neurodevelopmental Disorders. | Kurishev AO et al. | β | 2022 | β |
| Evaluation of advances in cortical development using model systems. | Nano PR et al. | β | 2022 | β |
| Impact of schizophrenia GWAS loci converge onto distinct pathways in cortical interneurons vs glutamatergic neurons during development. | Liu D et al. | β | 2022 | β |
| Using Stem Cell Models to Explore the Genetics Underlying Psychiatric Disorders: Linking Risk Variants, Genes, and Biology in Brain Disease. | Brennand KJ | β | 2022 | β |
| A human iPSC-astroglia neurodevelopmental model reveals divergent transcriptomic patterns in schizophrenia. | Szabo A et al. | β | 2021 | β |
| Analysis framework and experimental design for evaluating synergy-driving gene expression. | Schrode N et al. | β | 2021 | β |
| Applying stem cells and CRISPR engineering to uncover the etiology of schizophrenia. | Michael Deans PJ et al. | β | 2021 | β |
| CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility. | Goell JH et al. | β | 2021 | β |
| CRISPR-Cas Gene Perturbation and Editing in Human Induced Pluripotent Stem Cells. | van Essen M et al. | β | 2021 | β |
| Epigenetic principles underlying epileptogenesis and epilepsy syndromes. | Conboy K et al. | β | 2021 | β |
| Massively Parallel Reporter Assays: Defining Functional Psychiatric Genetic Variants Across Biological Contexts. | Mulvey B et al. | β | 2021 | β |
| Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis. | Ma M et al. | β | 2021 | β |
| Transformative Network Modeling of Multi-omics Data Reveals Detailed Circuits, Key Regulators, and Potential Therapeutics for Alzheimer's Disease. | Wang M et al. | β | 2021 | β |
| Using the dCas9-KRAB system to repress gene expression in hiPSC-derived <i>NGN2</i> neurons. | Li A et al. | β | 2021 | β |
| A multiplexed gRNA piggyBac transposon system facilitates efficient induction of CRISPRi and CRISPRa in human pluripotent stem cells. | Hazelbaker DZ et al. | β | 2020 | β |
| Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer's disease. | Schrauben M et al. | β | 2020 | β |
| ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs. | Barretto N et al. | β | 2020 | β |
| A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose. | Joly JH et al. | β | 2020 | β |
| CRISPR-based functional evaluation of schizophrenia risk variants. | Rajarajan P et al. | β | 2020 | β |
| Decreased IL-1Ξ²-induced CCL20 response in human iPSC-astrocytes in schizophrenia: Potential attenuating effects on recruitment of regulatory T cells. | Akkouh IA et al. | β | 2020 | β |
| Effective restoration of dystrophin expression in iPSC <sup>Mdx</sup>-derived muscle progenitor cells using the CRISPR/Cas9 system and homology-directed repair technology. | Jin Y et al. | β | 2020 | β |
| Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges. | Pei WD et al. | β | 2020 | β |
| High-Throughput Screens of PAM-Flexible Cas9 Variants for Gene Knockout and Transcriptional Modulation. | Legut M et al. | β | 2020 | β |
| High-throughput single-cell functional elucidation of neurodevelopmental disease-associated genes reveals convergent mechanisms altering neuronal differentiation. | Lalli MA et al. | β | 2020 | β |
| Integrating CRISPR Engineering and hiPSC-Derived 2D Disease Modeling Systems. | Rehbach K et al. | β | 2020 | β |
| Integration of CRISPR-engineering and hiPSC-based models of psychiatric genomics. | Matos MR et al. | β | 2020 | β |
| Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells. | Powell SK et al. | β | 2020 | β |
| Massively parallel techniques for cataloguing the regulome of the human brain. | Townsley KG et al. | β | 2020 | β |
| Modeling the complex genetic architectures of brain disease. | Fernando MB et al. | β | 2020 | β |
| rs953413 Regulates Polyunsaturated Fatty Acid Metabolism by Modulating ELOVL2 Expression. | Pan G et al. | β | 2020 | β |
| CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity. | TadiΔ V et al. | β | 2019 | β |
| New considerations for hiPSC-based models of neuropsychiatric disorders. | Hoffman GE et al. | β | 2019 | β |
| Synergistic effects of common schizophrenia risk variants. | Schrode N et al. | β | 2019 | β |
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | Prytkova I et al. | β | 2018 | β |
| Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells. | LaMarca EA et al. | β | 2018 | β |
| Neuron-specific signatures in the chromosomal connectome associated with schizophrenia risk. | Rajarajan P et al. | β | 2018 | β |
| Applications of CRISPR/Cas9 in the Mammalian Central Nervous System. | Savell KE et al. | β | 2017 | β |
| CRISPR/Cas9-Based Engineering of the Epigenome. | Pulecio J et al. | β | 2017 | β |